Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Bermejo

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2011
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trialD Rayson, T M Suter, C Jackisch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancerJ Albanell, A González, M Ruiz-Borrego, et al.
ESMO Open|January 22, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1C Vaklavas, M Oliveira, A C Armstrong, et al.
ESMO Open|November 7, 2025
Comparing [<sup>18</sup>F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trialJ J García-Mosquera, J M Pérez-García, M Ruiz-Borrego, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockadeP Nuciforo, T Pascual, J Cortés, et al.
NPJ Precision Oncology|March 20, 2021
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancerG Griguolo, G Serna, T Pascual, et al.
ESMO Open|October 1, 2024
Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES studyÁ Guerrero-Zotano, J M Pérez-García, M Ruiz-Borrego, et al.
BMC Cancer|November 10, 2020
Combination of phenotype and polygenic risk score in breast cancer risk evaluation in the Spanish population: a case -control studyJ C Triviño, A Ceba, E Rubio-Solsona, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 17, 2019
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere studyJ Gavilá, J De La Haba, B Bermejo, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 10, 2022
Impact of the COVID-19 Pandemic on a Cancer Fast-Track ProgrammeM T Martínez, S Moragon, B Ortega-Morillo, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2011
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trialD Rayson, T M Suter, C Jackisch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancerJ Albanell, A González, M Ruiz-Borrego, et al.
ESMO Open|January 22, 2026
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1C Vaklavas, M Oliveira, A C Armstrong, et al.
ESMO Open|November 7, 2025
Comparing [<sup>18</sup>F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trialJ J García-Mosquera, J M Pérez-García, M Ruiz-Borrego, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockadeP Nuciforo, T Pascual, J Cortés, et al.
NPJ Precision Oncology|March 20, 2021
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancerG Griguolo, G Serna, T Pascual, et al.
ESMO Open|October 1, 2024
Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES studyÁ Guerrero-Zotano, J M Pérez-García, M Ruiz-Borrego, et al.
BMC Cancer|November 10, 2020
Combination of phenotype and polygenic risk score in breast cancer risk evaluation in the Spanish population: a case -control studyJ C Triviño, A Ceba, E Rubio-Solsona, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 17, 2019
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere studyJ Gavilá, J De La Haba, B Bermejo, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 10, 2022
Impact of the COVID-19 Pandemic on a Cancer Fast-Track ProgrammeM T Martínez, S Moragon, B Ortega-Morillo, et al.
Pageof 10